This page features KEI blog posts, testimony, comments, and research on the transparency of the costs of research and development in the pharmaceutical sector.
United States Transparency Legislation
10 March 2017: 2017 R&D Cost Transparency Proposals in the United States
2013. Manon Anne Ress. Global Public Goods, transnational public goods: some definitions : How are global public goods defined? Definitions of 'global public goods' as outlined by major contributors to the international debate. (html)
Manon's 2013 collection of quotes is very relevant, but here are some additional definitions. The discussions by Musgrave and Steiner are probably closer to how people actually define public or social goods in practice.
How are global public goods defined? Definitions of 'global public goods' as outlined by major contributors to the international debate.
Manon Anne Ress,
August 23, 2013
World Health Organization WHO Definition
Enhanced Charitable Deductions for Businesses, Counting on Charity, An accounting professor's view of the nonprofit world. WEDNESDAY, JANUARY 30, 2013
Anil Arya and Brian Mittendorf, The Economic Consequences of Enhanced Charitable Tax Deductions, March 1, 2013. http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2208095
Notes on the Blur Banff proposal*
KEI Research Note 2013:1
February 1, 2013
This is a brief note on the Blur/Banff proposal for a system of decentralized decision making and competitive intermediaries to provide money to support recorded music that is freely available. Also discussed are extensions of the competitive intermediary approach to other areas where information goods can be supplied as public goods.
2011: Survey of drug prices for 14 drugs with US government rights in patents listed in the FDA Orange Book
Survey of drug prices for 14 drugs with US government rights in patents listed in the FDA Orange Book
Knowledge Ecology International
November 11, 2011
The data tables from the annual Pharma industry profile surveys are attached below.
A few notes from the tables.
In 2002, the number of data tables in was 19. In 2003, the number of tables was reduced to 9. In 2012, the number of tables was 10.
Prices for Abbott's Norvir (generic name Ritonavir) as a Standalone Product in 2010, KEI Research Note 2010:4
KEI Research Note 2010:4
August 12, 2010
Anne Mira Guha